Pulmonary Sarcoidosis Lung Function Medication

Trial Objective

Pulmonary Sarcoidosis Lung Function MedicationResearchers are trying to determine if an investigational medication called CMK389 improves lung function for people with chronic pulmonary sarcoidosis. The study also will determine if the drug is safe and well-tolerated in study participants.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

People with pulmonary sarcoidosis who are on a stable treatment of prednisone for at least six months prior to starting the study.

Age: 18-75    Gender: Any Gender


Estimated Time Commitment

13 clinic visits lasting 4-8 hours each over 9 to 11 months



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Cindy Wainscoat
303.398.1259

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Novartis Pharmaceuticals Corporation

Principal Investigators

Co-Investigators


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.


*
*
*
*
 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: